Table F- 32Rosiglitazone compared with metformin

Domains pertaining to strength of evidenceMagnitude of effectStrength of evidence
Number of Studies; # of SubjectsRisk of Bias (Design/Quality)ConsistencyDirectnessPrecisionSummary Effect Size (95% Confidence Interval)High, Moderate, Low, Insufficient
HbA1c
4;
8925
Medium
RCTs/Fair
ConsistentIndirectPreciseNo difference (3 of 4 trials found no difference; 1 reported a very small difference favoring rosiglitazone, 0.13% between group difference)Moderate
Weight change
3;1182Medium
RCT/Fair
InconsistentIndirect (intermediate outcome)PreciseWeight gain with rosiglitazone compared with weight loss with metforminModerate

From: Appendix F, Strength of evidence

Cover of Drug Class Review: Newer Diabetes Medications, TZDs, and Combinations
Drug Class Review: Newer Diabetes Medications, TZDs, and Combinations: Final Original Report [Internet].
Jonas D, Van Scoyoc E, Gerrald K, et al.
Portland (OR): Oregon Health & Science University; 2011 Feb.
Copyright © 2011, Oregon Health & Science University.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.